Saltar al contenido
Merck

Mutations in DYNC2LI1 disrupt cilia function and cause short rib polydactyly syndrome.

Nature communications (2015-06-17)
S Paige Taylor, Tiago J Dantas, Ivan Duran, Sulin Wu, Ralph S Lachman, Stanley F Nelson, Daniel H Cohn, Richard B Vallee, Deborah Krakow
RESUMEN

The short rib polydactyly syndromes (SRPSs) are a heterogeneous group of autosomal recessive, perinatal lethal skeletal disorders characterized primarily by short, horizontal ribs, short limbs and polydactyly. Mutations in several genes affecting intraflagellar transport (IFT) cause SRPS but they do not account for all cases. Here we identify an additional SRPS gene and further unravel the functional basis for IFT. We perform whole-exome sequencing and identify mutations in a new disease-producing gene, cytoplasmic dynein-2 light intermediate chain 1, DYNC2LI1, segregating with disease in three families. Using primary fibroblasts, we show that DYNC2LI1 is essential for dynein-2 complex stability and that mutations in DYNC2LI1 result in variable length, including hyperelongated, cilia, Hedgehog pathway impairment and ciliary IFT accumulations. The findings in this study expand our understanding of SRPS locus heterogeneity and demonstrate the importance of DYNC2LI1 in dynein-2 complex stability, cilium function, Hedgehog regulation and skeletogenesis.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Fluoruro de fenilmetansulfonilo, ≥98.5% (GC)
Sigma-Aldrich
Anti-α-tubulina monoclonal antibody produced in mouse, clone DM1A, ascites fluid
Sigma-Aldrich
Monoclonal Anti-Tubulin, Acetylated antibody produced in mouse, clone 6-11B-1, ascites fluid
Sigma-Aldrich
Fluoruro de fenilmetansulfonilo, ≥99.0% (T)
Sigma-Aldrich
Anti-KIF3A antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-WDR34 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Dync2li1